HIV/AIDS
Conditions
Interventions
Case series:DTG 50mg +3TC 300mg once a day
Sponsors
The Fifth Affiliated Hosipital Of Sun Yat-sen University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years old, male or female; 2. Confirmed HIV-1 infection; 3. judgment, for any reason. For example, (but not limited to) patients who cannot tolerate the national first-line treatment regimen and cannot use the national standard three-drug treatment regimen due to renal insufficiency or osteoporosis; 4. HIV-RNA iral load and CD4 cell count were not limited; 5. CD4 can be detected at least 3 times in the first year (including baseline and 24 weeks of treatment).CD4 should be tested at least once every six months; 6. informed consent for treatment has been signed.
Exclusion criteria
Exclusion criteria: 1. participated in clinical trials of HIV vaccine or other drug trials within the past three months; 2. evidence of drug addiction (including excessive alcohol intake) in the year prior to the trial; 3. a clear history of DTG or 3TC allergy; 4. hepatitis B surface antigen (HBsAg) and/or HBV-DNA positive; 5. pregnant or lactating women; 6. other history or evidence of chronic liver disease (e.g. hemochromia, autoimmune hepatitis, alcoholic liver disease, toxic exposure, thalassemia); 7. a history of serious mental illness, especially depression.A serious mental illness is one that has been on antidepressants or used to treat depression or mental illness for at least three months at any time in the past; 8. therapeutic doses of sedatives, or any history of suicide attempts, hospitalization for mental illness, incapacity to work for a period of time due to mental illness; 9. a history of severe epilepsy or currently being treated with sedatives; 10. immune-mediated disease, or evidence of other severe or malignant diseases, or other conditions of the patient that make the investigator consider him/her unsuitable to participate in this study; 11. the researcher judged that the patients could not complete the scheduled follow-up; 12. inability or unwillingness to provide informed consent or comply with test requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Virological breakthrough rate (HIV RNA <400 copies/mL);CD4+T lymphocyte count; | — |
Countries
China
Contacts
Public ContactJinyu Xia
The Fifth Affiliated Hosipital Of Sun Yat-sen University
Outcome results
None listed